Compare TechnipFMC plc Ordinary Share (FTI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TechnipFMC plc Ordinary Share vs Spyre Therapeutics Inc. Common Stock — how do they compare? TechnipFMC plc Ordinary Share trades at $69.36 (market cap $27.73B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: TechnipFMC plc Ordinary Share is far larger — about 3.7× Spyre Therapeutics Inc. Common Stock's market cap, and TechnipFMC plc Ordinary Share pays a 0.28% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FTI | SYRE | |
|---|---|---|
Market Cap | $27.73B | $7.52B |
Volume | 2,487,618 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $80.08 | $108.92 |
52-Week Low | $35.57 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $27.98B | $6.52B |
Dividend Yield | 0.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTI trades at $70.72, up 1.39% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 36.04% ROE and 11.28% net margin. Recent Petrobras contract wins and strategic hires strengthen its subsea and consulting capabilities. Analyst consensus remains bullish with a $80.50 price target representing 14% upside potential.
FTI presents a compelling growth story with consistent earnings outperformance and strategic expansion, though technical indicators suggest near-term consolidation. The primary risk involves execution of recent contracts and maintaining profitability amid rising expenses. With zero sell ratings and institutional accumulation, the stock offers upside potential for investors comfortable with energy sector volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TechnipFMC plc Ordinary Share
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
